Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.49 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604775 | 0.89 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL12990966 | 0.89 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL12991415 | 0.87 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL12991519 | 0.85 | TRPV1 (0.51) | TRPV1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12990980 | 0.81 | LMNA (0.51) | HRH3TRPV1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3589725 | 0.80 | RAB9A (0.47) | NPC1RAB9AALDH1A1SMN1; SMN2JMJD6 | |
| SCHEMBL28813537 | 0.79 | RAB9A (0.51) | NPC1RAB9AALDH1A1SMN1; SMN2JMJD6 | |
| SCHEMBL12991874 | 0.79 | TRPV1 (0.45) | DGAT1SOAT1TRPV1ALDH1A1 | |
| SCHEMBL12992344 | 0.79 | HRH3 (0.49) | KCNH2HRH3ALDH1A1 | |
| SCHEMBL12991869 | 0.78 | ALDH1A1 (0.49) | HRH3TRPV1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20070167444-A1 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1632477-A1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | TRPV1, TRPV2, TRPV3 | KCNH2 164/4885HRH3 126/4885DGAT1 2057/4885 |
| US-20070167444-A1 | Benzamide derivative or salt thereof | TRPV1, BDKRB1, BDKRB2 | KCNH2 208/4885HRH3 83/4885DGAT1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.